UK announces research plan on evolving global health threats
September 26, 2019Research and Development
The UK’s Chief Medical Officer, Professor Dame Sally Davies has announced funding for projects to help combat antimicrobial resistance (AMR) …
NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland
September 26, 2019Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma
NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …
Springworks’ nirogacestat receives EC orphan status
September 26, 2019Research and Development
Springworks, a clinical-stage biopharmaceutical company focusing on severe rare disease and cancer has been granted orphan status by the European …
Corbyn announces plan to ‘put public health before private profit’
September 25, 2019Research and Development
Jeremy Corbyn has announced a new plan to set up a state-run drugs manufacturer to sell cheap medications to the …
Takeda’s investigational therapy shows promise as cytomegalovirus treatment
September 25, 2019Research and Development, Sales and Marketing Takeda, cytomegalovirus, maribavir, pharma
New Phase 2 data has been released on Takeda’s investigational antiviral therapy TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection …
Novartis blames former AveXis execs for Zolgensma data manipulation
September 25, 2019Research and Development
Novartis has placed blame on former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million …
EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma
September 25, 2019Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …
Ipsen announces positive phase 3 results in limb spastic hemiparesis
September 24, 2019Manufacturing and Production, Research and Development
Ipsen has announced results from its ENGAGE study for the combination of Dysport (abobotulinumtoxinA) alongside Guided Self-rehabilitation contracts (GSC) which …
Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation
September 24, 2019Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …
Evotec and Takeda enter into multi therapeutic area collaboration
September 24, 2019Manufacturing and Production, Research and Development
Evotec have announced a strategic, multi-year drug discovery collaboration with Takeda, with both companies aiming to establish at least five …
Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy
September 24, 2019Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Cancer, Vitravki, pharma
Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …
Medicinal cannabis product Epidyolex approved in EU for childhood epilepsy
September 24, 2019Manufacturing and Production, Research and Development
GW Pharmaceuticals, a world leader in the development of cannabinoid prescription drugs has announced it has received approval from the …
Destiny Pharma’s Joe Eagle to step down from Board
September 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs to address the global crisis …
Living with acute myeloid leukaemia
September 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute myeloid leukaemia, feature, patient experience, pharma
Steve Rothberg was blindsided by an AML diagnosis that progressed rapidly with little warning. Ten years later, he discusses his …
Bluebird bio’s Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy
September 23, 2019Research and Development, Sales and Marketing Bluebird Bio, cerebral adrenoleukodystrophy, gene therapy, pharma
Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a …
Servier on trial for weight-loss pill that led to 2,000 deaths
September 23, 2019Sales and Marketing
A trial on one of France’s largest ever healthcare scandals has begun after a weight loss pill was believed to …
Japan approves Astellas and FibroGen’s Evrenzo for anaemia in dialysis patients
September 23, 2019Sales and Marketing Astellas, anaemia, fibrogen, pharma
Astellas Pharma and FibroGen have revealed that their collaborative drug Evrenzo (roxadustat) has secured marketing authorisation in Japan for the …
EMA’s CHMP recommends three new medications
September 23, 2019Sales and Marketing
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) have recommended approval for three new medicines with …
FDA approves Novo’s new type 2 diabetes pill
September 23, 2019Sales and Marketing
A new drug from Danish drug maker Novo Nordisk, called Rybelsus (semaglutide), has been approved by the FDA for the …
Top Ten most popular articles on Pharmafile.com this week
September 20, 2019Medical Communications
Friday time! This past week has seen numerous potential breakthroughs including a prostate drug that could halt Parkinson’s disease as …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
